Changchun Changsheng bankruptcy auction: in the research vaccine 157 million yuan starting!

Following the announcement of the bankruptcy of Changchun Evergreen Biotech Co., Ltd. on November 8, 2019, there is now a bankruptcy auction news of Changchun Changsheng.
According to the public information on Taobao Ali's auction bankruptcy platform, Changchun Changsheng Bio bankruptcy administrator will conduct a centralized auction of some of the assets held by Changchun Changsheng Bio from 10 a.m. on July 24 to 10 a.m. on July 25.
, the shingles vaccine held by Changchun Changsheng will start at a price of 156.79 million yuan, with a price increase of 700,000 yuan and a required margin of 30 million yuan. The supervisory unit of the
auction is the Changchun Intermediate People's Court of Jilin Province.
defects According to the auction announcement, the auction may constitute the underlying defects: 1. The project in the study has been discontinued since 2018, although the experimental sampleist is currently in preservation, but in view of the interruption of research and development, whether the test can continue to be tested and whether the experimental data can continue to apply and test the results are uncertain.
please carefully consider the timeliness, continuity, etc. of the experimental data.
2. The research project in the name of Changchun Evergreen company to carry out clinical trial declaration, before the suspension has completed part of the clinical trial stage, the previously formed data are based on Changchun Evergreen company's premises, equipment and other objective conditions, such as continuing clinical trials, there will be subject and objective conditions of change, whether there is uncertainty, may have a greater impact on the value of the research project.
3. The application for clinical trial of the vaccine research and development project, the approval number of the drug, etc., shall be subject to the examination by the relevant competent departments of the state, and the prospecting buyer shall consult the relevant departments on its own.
manager sit on the follow-up research and development, use, etc. in this research project, do not make a commitment.
auction announcement other information consultation samples from June 24, 2020 to July 21, 2020 (holidays closed) to receive consultation.
if necessary and qualified, the manager may cooperate with the sample, interested parties please contact the manager on specific matters.
if for objective reasons do not have the conditions to look, please intend to bid for their own inspection.
The conditions of the bidder 1. All citizens, legal persons and other organizations with full capacity for civil conduct may participate in the bidding, and if they do not have full civil capacity, their clients or agents must have full civil capacity;
2. The bidder may entrust an agent (a natural person with full civil capacity) to carry out the entrustment procedures, provided that the bid is successfully conducted with the manager for entrustment procedures;
if the entrustment procedures are incomplete, the bidding activity is recognized as the personal act of the entrusting agent.
3. If the bidder participates in the bidding competition because he does not meet the conditions, the bidder shall bear the corresponding legal liability.
Preferred PurchaseR 1. Relevant Notes of the Pre-PurchaseR of the Subject matter: No 2. If the first right-to-buy person participates in the bidding, it shall submit a valid certificate of legality to the manager before July 21, 2020, and the qualification shall be confirmed by the manager before it can participate in the bidding, and if it is not submitted within the time limit, it shall be deemed to give up the right of priority purchase of the subject matter.
3. Where the preferred right holder participates in the bidding, the auction property is bid by the preferred right holder if the other bidder bids at the same price as the other bidders and there is no higher bid.
4. Where the preferred right holder of the order applies for participation in the bidding, the manager shall confirm its order and give a different order of priority bidding code. If the preferred rightholder of the
is bid at the same price, the auction property shall be bid by the first priority purchaser in the order. if the
the preferred right holder bids at the same price, the auction property is bid by the preferred right holder who bids first.
the case of the shingles vaccine by querying the national drug regulatory agency database, domestic information on the market of the shingles vaccine, only one of the imported drugs, the manufacturer is GlaxoSmithKline Biological Products (Belgium), approved the listing on May 21, 2019.
according to publicly available information, shingles is an infectious skin disease caused by the reactivation of the chickenpox-shinghers virus lurking in the body.
in addition to the rash, the disease will also cause nerve damage, patients will appear nerve pain, itching and other symptoms, some patients have long duration of neurological symptoms, chronic pain will also cause emotional disorders, such as anxiety, depression, and even more serious conditions, seriously affecting the quality of life of patients.
vaccination is the most effective way to prevent the onset of the disease.
the FDA first approved Merck's live shingles-reducing vaccine in 2006 and has not been available domestically.
2017, the U.S. FDA approved GSK's recombinant shingles vaccine for the market, and in 2019 the vaccine will be approved for entry into the Chinese market, starting in early July in Beijing and Shanghai.
in China, including 10 grams of biology, Wantai biology, Watson biology, Zhifei biology, Dalian Yalifeng, Shanghai Institute of Biological Products, Changchun Jian, Beijing Green Bamboo Biology, Kangshino and other companies are in the layout of shingles vaccine.
other auctions and related assets associated with the project's same period include some vehicles and properties under the name of Changchun Changsheng Bio.
, a Danaken small ordinary bus and Audi small ordinary bus starting prices of more than 400,000 yuan, located in Changchun City, a property starting at 1.067 million yuan, and located in The Chongwen District of Beijing, a property starting price of more than 10 million yuan.
According to public reports, Changchun Evergreen has conducted several asset auctions in March and April this year, with two assets being auctioned.
one of them, "Phage low endotoxin super-newborn bovine serum", sold for $1,532.865 million on March 17.
another 7.2% stake in Beijing Xiangrui Biological Products Co., Ltd., which was sold on April 28 by shanghai Parkahui, a major shareholder, for a starting price of 1708.2416 million yuan, bringing its stake in Beijing Xiangrui Co., Ltd. to 75.15 percent.
other assets end up with a flow mark.
Long-lived biological vaccine event timeline July 15, 2018 The State Drug Administration issued a notice through its official website, said that the State Drug Administration found Changchun long-living freeze-dried human rabies vaccine production records fraud and other serious violations of the "Drug Production Quality Management Code."
Jilin Province Food and Drug Administration has withdrawn Changchun Changsheng 'Drug GMP Certificate', and has stopped the production of rabies vaccine as required.
Changchun Changsheng is carrying out a recall of all batches of the freeze-dried human rabies vaccine (vero cells) during the validity period.
July 16, 2018, Li Keqiang has issued a notice on the vaccine incident, asking for a thorough investigation.
July 18, 2018, the multi-site disease control department discontinued and sealed the Changchun Long Live Rabies Vaccine.
July 23, 2018, changchun Changchun New District Public Security Bureau, in accordance with the Jilin Province Food and Drug Administration's "Suspected Crime Transfer Book", the Changchun Evergreen Biotech Co., Ltd. to produce freeze-dried human rabies vaccine suspected of illegal crime cases quickly opened an investigation, the main involved in the company's chairman Gao Afang (female) and four company executives to the public security organs for legal examination.
July 23, 2018, Xi Jinping, General Secretary of the Communist Party of China (CPC) Central Committee and President of the Central Military Commission (CMC), who is visiting abroad, gave important instructions on the case of Changchun Changsheng Biovaccines in Jilin Province, noting that Changchun Changsheng Biotech Co., Ltd. illegally and illegally produced vaccines, which is of a shocking nature.
relevant local authorities and departments should attach great importance to the immediate investigation of the truth, a check to the end, serious accountability, strict treatment in accordance with the law.
August 16, 2018, the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting on August 16, with a total of 42 accountability personnel, four of the seven cadres at the ministerial level who were dismissed, one who was opened and two others undergoing in-depth inspections.
agreed to remove Jin Yuhui (deputy governor of Jilin Province, who has been in charge of food and drug regulation in Jilin Province since April 2017) and Li Jinxiu (Vice Chairman of the Jilin Provincial Committee of the Chinese People's Political Consultative Conference, From December 2015 to April 2017) Vice Governor of Food and Drug Administration) ordered his resignation and asked Liu Changlong (Mayor of Changchun City, acting mayor of Changchun City in September 2016, mayor of Changchun City from October 2016 to date), Bi Jingquan (Party Secretary and Deputy Director of the General Administration of Market Supervision, 20 February 15- March 2018 as the former Director General of the General Administration of Food and Drug Administration) resigned, asked Jiang Zhiying (the Jilin Provincial Standing Committee, Yanbian Korean Autonomous Prefecture Party Secretary, March 2012-May 2016 as deputy secretary of the Changchun Municipal Committee, mayor), Jia Hong (Director of the State Drug Administration) to make a profound inspection; pharmaceutical supervision and audit and inspection work) to conduct a case review and investigation. The
meeting tasked the Jilin Provincial Committee and the provincial government and the State Drug Administration to make in-depth inspections to the CPC Central Committee and the State Council.
August 17, 2018, the State Administration of Market Supervision and Administration of the Party Group meeting decided: the former State Food and Drug Administration (State Drug Administration) Director of the Drug and Cosmetics Supervision Department, The Director of the Food and Drug Audit and Inspection Center Ding Jianhua was removed from office; Jinglin (formerdeputy deputy director of the Food and Drug Administration's Food and Drug Administration Audit and Inspection Center from November 2014 to April 2017) was removed from office; Ye Guoqing, director of the Special Drug Supervision Department of the Drug and Cosmetics Supervision Department of the State Administration of Food and Drug Administration (State Drug Administration) was removed from office, and Guo Xiu-man, former Director of the Special Drug Supervision Department of the State Food and Drug Administration (State Drug Administration) was removed from office. Wang Youchun, vice president of the China Food and Drug Inspection Research Institute, was removed from his post and Li Bo, president (director) of the China Food and Drug Administration (formerly the Medical Device Standards Management Center of the State Food and Drug Administration) was tasked with conducting in-depth inspections.
October 16, 2018, the main subsidiary of Changsheng Biotech Co., Ltd. (Changsheng Bio) was sentenced by the State Drug Administration to an administrative penalty decision to revoke the license for drug production for illegal production of vaccines, and fined 9.1 billion yuan for non-payment.
November 16, 2018, the Shenzhen Stock Exchange informed the outside world that the Shenzhen Stock Exchange had launched a mandatory de-listing mechanism for major illegal violations of evergreen organisms on the same day, as the long-lived creatures may have touched on the situation of forced de-listing of major violations of the law.
October 16, 2019, after a six-month suspension of listing, Shenzhen Stock Exchange listed company Changsheng Bio entered the de-listing period, 30 trading days later, will be delisted by the Shenzhen Stock Exchange, Changsheng Bio will be forced to delist the first share of the identity of the A-share because of major violations of the identity recorded in the history of The A-share.
November 8, 2019, the Shenzhen Stock Exchange website published the "Announcement of Changsheng Biotech Co., Ltd. on the bankruptcy liquidation of the company's wholly-owned subsidiary", declaring Changchun Evergreen Biotech Co., Ltd. bankrupt.
November 27, 2019, the shares of Evergreen Bioshares were delisted.
.